Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 2/20 | 0.49 |
| ▸ | DHFR | P00374 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.44 |
| ▸ | P2RX2 | Q9UBL9 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27035942 | 1.00 | NUDT1 (0.49) | NUDT1DHFRP2RX3P2RX2MAPT | |
| SCHEMBL27532126 | 0.89 | NUDT1 (0.47) | NUDT1DHFRP2RX3P2RX2MAPT | |
| SCHEMBL2897696 | 0.84 | NUDT1 (0.58) | NUDT1DHFRP2RX3P2RX2MEN1 | |
| SCHEMBL27053669 | 0.82 | NUDT1 (0.47) | NUDT1P2RX3P2RX2 | |
| SCHEMBL27150294 | 0.82 | NUDT1 (0.43) | NUDT1DHFRP2RX3P2RX2MAPT | |
| SCHEMBL26978045 | 0.81 | NUDT1 (0.46) | NUDT1DHFRP2RX3P2RX2MEN1 | |
| SCHEMBL31615264 | 0.80 | NUDT1 (0.44) | NUDT1DHFRP2RX3P2RX2MEN1 | |
| SCHEMBL29082598 | 0.80 | NUDT1 (0.51) | NUDT1P2RX3P2RX2MAPTMEN1 | |
| SCHEMBL30559743 | 0.80 | NUDT1 (0.44) | NUDT1DHFRP2RX3P2RX2MEN1 | |
| SCHEMBL30559753 | 0.80 | NUDT1 (0.44) | NUDT1DHFRP2RX3P2RX2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | GPR17, GPR27, GPR119 | NUDT1 2813/4885DHFR 2001/4885P2RX3 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.